Digoxin and Risk of Death in Adults With Atrial Fibrillation: The ATRIA-CVRN Study
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background—: Digoxin remains commonly used for rate control in atrial fibrillation, but limited data exist supporting this practice and some studies have shown an association with adverse outcomes. We examined the independent association between digoxin and risks of death and hospitalization in adults with incident atrial fibrillation and no heart failure. Methods and Results—: We performed a retrospective cohort study of 14 787 age, sex, and high-dimensional propensity score-matched adults with incident atrial fibrillation and no previous heart failure or digoxin use in the AnTicoagulation and Risk factors In Atrial fibrillation-Cardiovascular Research Network (ATRIA-CVRN) study within Kaiser Permanente Northern and Southern California. We examined the independent association between newly initiated digoxin and the risks of death and hospitalization using extended Cox regression. During a median 1.17 (interquartile range, 0.49–1.97) years of follow-up among matched patients with atrial fibrillation, incident digoxin use was associated with higher rates of death (8.3 versus 4.9 per 100 person-years; P <0.001) and hospitalization (60.1 versus 37.2 per 100 person-years; P <0.001). Incident digoxin use was independently associated with a 71% higher risk of death (hazard ratio, 1.71; 95% confidence interval, 1.52–1.93) and a 63% higher risk of hospitalization (hazard ratio, 1.63; 95% confidence interval, 1.56–1.71). Results were consistent in subgroups of age and sex and when using intent-to-treat or on-treatment analytic approaches. Conclusions—: In adults with atrial fibrillation, digoxin use was independently associated with higher risks of death and hospitalization. Given other available rate control options, digoxin should be used with caution in the management of atrial fibrillation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A comparison of rate control and rhythm control in patients with atrial fibrillation
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa021328 · Cited by 4,405
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Schneeweiss, S., Rassen, J. A., Glynn, R. J., Avorn, J., Mogun, H., & Brookhart, M. A. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181a663cc · Cited by 1,128 · cited 1×
“The algorithm selects the most frequent 200 items from each of these three dimensions within a five-year look-back period and after that selects the 300 best matched parameters out of the initial 600 items for use in the high-dimensional propensity score.(33) This methodology has been shown to approximate point estima…”
MethodLenient versus strict rate control in patients with atrial fibrillation
Van Gelder, I. C., Groenveld, H. F., Crijns, H. J. G. M., Tuininga, Y. S., Tijssen, J. G. P., Alings, A. M., Hillege, H. L., Bergsma-Kadijk, J. A., Cornel, J. H., Kamp, O., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001337 · Cited by 1,033
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Kay, G. N., Le Huezey, J.-Y., Lowe, J. E., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318214876d · Cited by 859
Koebnick, C., Langer-Gould, A. M., Gould, M. K., Chao, C. R., Iyer, R. L., Smith, N., Chen, W., & Jacobsen, S. J. (2012) · The Permanente Journal · doi:10.7812/tpp/12-031 · Cited by 789
Bronstein, A. C., Spyker, D. A., Cantilena, L. R., Green, J. L., Rumack, B. H., & Dart, R. C. (2011) · Clinical Toxicology · doi:10.3109/15563650.2011.635149 · Cited by 388
Farshi, R., Kistner, D., Sarma, J. S. M., Longmate, J. A., & Singh, B. N. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00561-0 · Cited by 363
Increased mortality among patients taking digoxin—analysis from the AFFIRM study
Whitbeck, M. G., Charnigo, R. J., Khairy, P., Ziada, K., Bailey, A. L., Zegarra, M. M., Shah, J., Morales, G., Macaulay, T., Sorrell, V. L., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs348 · Cited by 279
Increased Mortality Associated With Digoxin in Contemporary Patients With Atrial Fibrillation
Turakhia, M. P., Santangeli, P., Winkelmayer, W. C., Xu, X., Ullal, A. J., Than, C. T., Schmitt, S., Holmes, T. H., Frayne, S. M., Phibbs, C. S., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.060 · Cited by 208
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,171
Metadata
- Authors
- Freeman, J. V., Reynolds, K., Fang, M., Udaltsova, N., Steimle, A., Pomernacki, N. K., Borowsky, L. H., Harrison, T. N., Singer, D. E., & Go, A. S.
- Venue
- Circulation: Arrhythmia and Electrophysiology
- Published
- 2015-02
- Volume
- 8
- Issue
- 1
- Pages
- 49-58
- ISSN
- 1941-3084 (ISSN-L)
- 1941-3149
- OpenAlex
- W2112439830
- Cited by
- 80
- References
- 15
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Digoxin and Risk of Death in Adults With Atrial Fibrillation: The ATRIA-CVRN Study. https://app.cochat.ai/papers/10.1161/circep.114.002292
- The paper
- Freeman, J. V., Reynolds, K., Fang, M., Udaltsova, N., Steimle, A., Pomernacki, N. K., Borowsky, L. H., Harrison, T. N., Singer, D. E., & Go, A. S. (2015). Digoxin and Risk of Death in Adults With Atrial Fibrillation: The ATRIA-CVRN Study. Circulation: Arrhythmia and Electrophysiology. https://doi.org/10.1161/circep.114.002292
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.